This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
We have developed an innovative technology which is going to revolutionize the cardiovascular disease diagnostic approach and help to avoid unnecessary invasive procedures.
Quick, safe and accurate diagnostic tool for assessing coronary artery disease severity
Detailed anatomical and functional evaluation of coronary arteries
The FFR-CT-based technology developed by HEMOLENS allows for a detailed anatomical and functional evaluation of coronary arteries.
The foundation of our testing methods is our innovative technology based on computational fluid mechanics.
I truly believe that together with Hemolens Diagnostics we will develop a new standard that will allow us to apply the non-invasive FFR-CT diagnostic tool in patients with intermediate-risk coronary artery disease. These are patients who, considering the contraindications, would not be eligible for invasive diagnostic work-up.
With FFR-CT, Hemolens Diagnostics offers a promising new technology to detect anatomically and functionally significant coronary artery stenosis on the basis of non-invasive examinations: coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure (CNBP) monitoring. Methods based on measuring fractional flow reserve (FFR) from computed tomography scans of coronary arteries are recommended by international scientific associations.
I became involved in the Hemolens Diagnostics project because I believe that advancements in technology can redefine the limits of existing testing procedures and provide clinical practitioners with ever more detailed insights. Non-invasive methods are the future of medicine.
